Infliximab
- Generic Name
- Infliximab
- Brand Names
- Avsola, Flixabi, Inflectra, Remicade, Renflexis, Zessly, Remsima
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 170277-31-3
- Unique Ingredient Identifier
- B72HH48FLU
- Background
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammato...
- Indication
用于治疗：
⑴类风湿性关节炎：本品常与甲氨蝶呤合用于中重度活动性类风湿性关节炎；
⑵克罗恩病及瘘管性克罗恩病；
⑶强直性脊柱炎等自身免疫性疾病，以减轻症状和体征，改善身体机能，预防患者残疾。
⑷用于银屑病关节炎的治疗【美国FDA已批准；英国风湿病学会/英国风湿病卫生专业人员协会《BSR／BHPR—应用生物制剂治疗银屑病关节炎指南》2012版；欧洲抗风湿病联盟《EULAR—银屑病关节炎药 物治疗管理建议》2011版
】。
⑸用于6岁及以上儿童溃疡性结肠炎的治疗【美国FDA已批准；中华医学会内科学会《炎症性肠病诊断与治疗的共识意见》；中华医学会消化病学分会炎症性肠病学组《英夫利西治疗克罗恩病的推荐方案（2011年】。
- Associated Conditions
- Ankylosing Spondylitis (AS), Chronic Plaque Psoriasis, Fistulizing Crohn's Disease, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Pediatric Crohn’s Disease, Psoriatic Arthritis
- Associated Therapies
- -
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-12-05
- Target Recruit Count
- 438
- Registration Number
- NCT05205603
- Locations
- 🇨🇳
People's Hospital of Chongqing, Chongqing, Chongqing, China
🇨🇳Shunde Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China
Combined Immunosuppression for Pediatric Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 128
- Registration Number
- NCT05043870
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT05034536
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Top Down Versus Step up in Pediatric Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT04999228
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 80
- Registration Number
- NCT04982172
- Locations
- 🇧🇪
UZ Leuven, Leuven, Vlaanderen, Belgium
Infliximab in the Treatment of Patients With Severe COVID-19 Disease
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Jena University Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT04922827
- Locations
- 🇩🇪
Universitätsklinikum Knappschaftskrankenhaus Bochum, Bochum, Germany
🇩🇪Jena University Hospital, Jena, Germany
🇩🇪Klinikum Fulda, Fulda, Germany
MIS-C Comparative Effectiveness Study
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 73
- Registration Number
- NCT04898231
- Locations
- 🇺🇸
Rady Children's Hospital, San Diego, California, United States
🇺🇸Children's Hospital Michigan, Detroit, Michigan, United States
A Cohort Study Comparing IFX to CS for Moderate to Severe UC
- Conditions
- Interventions
- First Posted Date
- 2021-05-10
- Last Posted Date
- 2022-11-25
- Target Recruit Count
- 342
- Registration Number
- NCT04879966
- Locations
- 🇨🇳
The Sixth Affiliated Hospital, Sun Yat-sen University, Guandong, China
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 196
- Registration Number
- NCT04835506
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
The Study of Infliximab (CMAB008 and Remicade) in Healthy Subjects to Compare the PK and Safety
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT04779892
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.